FDA Approves TRELSTAR — Verity Pharmaceuticals Inc.

Verity Pharmaceuticals Inc. has secured FDA approval for its supplement brand TRELSTAR (triptorelin pamoate), allowing the company to enter the market with an older neuroendocrine drug that addresses prostate cancer. This strategic expansion provides Verity with a stable revenue stream by offering a generic alternative to current TRT therapies, likely to appeal to cost-conscious healthcare providers.